PDC*line Pharma’s Phase I/II Trial Primary Clinical Results Selected for Mini Oral Presentation at ESMO-IO 2024
PDC*line Pharma is thrilled to announce that the primary clinical analysis results from our Phase I/II trial (PDC-LUNG-101) will be presented as a mini oral presentation at the European Society for Medical Oncology - Immuno-Oncology Congress 2024